.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Novartis
Johnson and Johnson
Cipla
McKesson
Express Scripts
Mallinckrodt
Chinese Patent Office
Cerilliant
McKinsey

Generated: June 27, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,784,878

« Back to Dashboard

Which drugs does patent 8,784,878 protect, and when does it expire?


Patent 8,784,878 protects AXIRON and is included in one NDA. There has been one Paragraph IV challenge on Axiron.

This patent has eighteen patent family members in eleven countries.

Summary for Patent: 8,784,878

Title:Transdermal delivery rate control using amorphous pharmaceutical compositions
Abstract: A pharmaceutical composition for transdermal delivery comprising one or more physiologically active agents; one or more dermal penetration enhancers; and a volatile pharmaceutically acceptable carrier comprising a volatile solvent; and wherein the physiologically active agent and dermal penetration enhancer form an amorphous deposit upon evaporation of the volatile carrier, said amorphous deposit forming a reservoir within the stratum corneum; and (A) wherein the composition has a release rate profile of physiologically active agent so as to provide a ratio of the maximum concentration (C.sub.max) to the average concentration (C.sub.avg) for the physiologically active agent over the dosage interval within the range of 1 to 10.
Inventor(s): Morgan; Timothy Matthias (Carlton North, AU), Wilkins; Nina Frances (Kensington, AU), Klose; Kathryn Traci-Jane (Bonreach, AU), Finnin; Barrie Charles (Toorak, AU), Reed; Barry Leonard (Essendon, AU)
Assignee: Acrux DDS Pty Ltc. (West Melbourne, Victoria, AU)
Application Number:13/710,761
Patent Claim Types:
see list of patent claims
Composition; Delivery; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Eli Lilly And Co
AXIRON
testosterone
SOLUTION, METERED;TRANSDERMAL022504-001Nov 23, 2010ATRXYesYes8,784,878► SubscribeY A METHOD OF TRANSDERMALLY DELIVERING TESTOSTERONE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,784,878

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,357,393Transdermal delivery rate control using amorphous pharmaceutical compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,784,878

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
New Zealand537360► Subscribe
South Korea20100055542► Subscribe
South Korea20050045946► Subscribe
Japan5568108► Subscribe
Japan2012162557► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Chinese Patent Office
UBS
Moodys
Boehringer Ingelheim
Julphar
Federal Trade Commission
Healthtrust
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot